MD Anderson study shows microbiome-based biomarkers may be used to predict to CAR T-cell therapy response

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

By investigating non-antibiotic-disrupted microbiomes, MD Anderson Cancer Center researchers developed a machine-learning algorithm that can predict long-term response to CAR T therapy using microbiome-based biomarkers. The study was published in Nature Medicine.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Two years ago, Dan Theodorescu made a discovery that could alter biology textbooks: The Y chromosome, widely considered to be a “functional wasteland,” has functions beyond sex determination—and in fact plays a role in cancer biology. 
First-line treatment with the triplet combination of encorafenib, cetuximab, and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the phase III BREAKWATER trial led by researchers from the University of Texas MD Anderson Cancer Center.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login